Ligand Pharmaceuticals Incorporated
LGND
$193.03
-$2.07-1.06%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 64.83% | 40.54% | 53.40% | 27.28% | -0.76% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 64.83% | 40.54% | 53.40% | 27.28% | -0.76% |
| Cost of Revenue | 198.12% | 139.92% | 134.41% | -7.28% | -44.89% |
| Gross Profit | 28.89% | 7.55% | 21.37% | 39.86% | 26.56% |
| SG&A Expenses | 34.74% | 50.38% | 63.57% | 48.99% | 1.64% |
| Depreciation & Amortization | -0.51% | 0.04% | -0.81% | -2.07% | -2.41% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 65.41% | 60.86% | 65.50% | 18.62% | -16.24% |
| Operating Income | 60.47% | -279.21% | -1,090.97% | 134.41% | 359.77% |
| Income Before Tax | 7.08% | -259.40% | -232.52% | -96.04% | -16.81% |
| Income Tax Expenses | 6.10% | -179.43% | -212.92% | -33.44% | -72.64% |
| Earnings from Continuing Operations | 7.38% | -280.02% | -237.65% | -107.49% | 114.46% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | 100.00% |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 7.38% | -280.02% | -237.65% | -107.73% | 174.52% |
| EBIT | 60.47% | -279.21% | -1,090.97% | 134.41% | 359.77% |
| EBITDA | 17.81% | -55.10% | -47.78% | 25.72% | 68.15% |
| EPS Basic | -9.12% | -264.26% | -230.86% | -101.63% | 172.62% |
| Normalized Basic EPS | 569.27% | -267.10% | -826.47% | 5.33% | 193.38% |
| EPS Diluted | -17.72% | -273.26% | -233.88% | -105.55% | 198.62% |
| Normalized Diluted EPS | 528.65% | -271.14% | -841.75% | 10.57% | 181.71% |
| Average Basic Shares Outstanding | 7.57% | 7.51% | 6.81% | 5.74% | 4.43% |
| Average Diluted Shares Outstanding | 8.96% | 7.45% | 5.22% | 3.93% | 3.25% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |